SynAct Pharma AB (OSTO:SYNACT) Moat Score: 0/10 (As of Jul. 03, 2026)


OSTO:SYNACT SynAct Pharma AB OSTO:SYNACT
19 GF Score
Price kr18.92
! 1 Warning Sign
View Full Analysis

What is SynAct Pharma AB Moat Score?

SynAct Pharma AB has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

SynAct Pharma AB has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes SynAct Pharma AB might have No Moat - No discernible moat.

SynAct Pharma AB  (OSTO:SYNACT) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

SynAct Pharma AB Moat Score Related Terms

OSTO:SYNACT
19GF Score
SynAct Pharma AB OSTO:SYNACT
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SynAct Pharma AB Business Description

Other Exchanges 8F8:Germany
Address Scheelevagen 2, Lund, SWE, 223 63
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolution activity to help patients achieve immune balance and overcome inflammation. AP1189, the company's drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
19GF Score

Get the complete analysis for OSTO:SYNACT

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr18.92
Price